AUY922
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myeloproliferative Neoplasms
Conditions
Myeloproliferative Neoplasms
Trial Timeline
Aug 1, 2012 → May 1, 2015
NCT ID
NCT01668173About AUY922
AUY922 is a phase 2 stage product being developed by Novartis for Myeloproliferative Neoplasms. The current trial status is terminated. This product is registered under clinical trial identifier NCT01668173. Target conditions include Myeloproliferative Neoplasms.
What happened to similar drugs?
0 of 1 similar drugs in Myeloproliferative Neoplasms were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01485536 | Phase 2 | Terminated |
| NCT01668173 | Phase 2 | Terminated |
| NCT01484860 | Phase 2 | Terminated |
| NCT01404650 | Phase 2 | Completed |
| NCT01124864 | Phase 2 | Completed |
| NCT01132625 | Phase 1 | Completed |
Competing Products
20 competing products in Myeloproliferative Neoplasms